Windlas Biotech Ltd
Ticker: WINDLAS
Decent
68/100
☆ Add to Watchlist
Investing Reference
Price
913.00
Market Cap
1913.59
Debt/Equity
0.0645
ROE %
12.763
PB
3.7835
Promoter %
62.337
Pledge %
0.000
1Y Rev Growth %
20.711
5Y Rev Growth %
18.612
NP Margin %
7.840
NP Margin 5Y Avg %
7.341
Trading Reference
1M Return %
-8.489
6M Return %
-14.649
1Y Return %
-8.503
% Away 52W High
31.243
% Away 52W Low
37.273
Daily Volume
39991
Investment Verdict
Hold
Score 66/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 21/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Windlas Biotech Ltd is currently trading near a key support level, with the 50-day EMA indicating a potential upward trend if it breaks the resistance at the recent highs. Volume has been increasing, suggesting bullish sentiment. Therefore, there is a moderate probability of upside in the medium term, while downside risk remains limited due to strong support levels.
Upside Probability: 15% | Downside Probability: 10%
Probability estimates are technical-context statements, not investment advice.
More Options
S
Spandana Sphoorty Financial Ltd
Spandana Sphoorty shows potential for growth in the microfinance sector, but faces challenges in profitability and valuation. Caution is advised.
View details
B
Balmer Lawrie Investments Ltd
Balmer Lawrie Investments Ltd shows moderate potential but faces challenges in growth consistency and valuation metrics.
View details
D
Dollar Industries Ltd
Dollar Industries Ltd shows potential but faces challenges in growth consistency and market sentiment.
View details
S
SEPC Ltd
SEPC Ltd shows potential in a growing sector but faces challenges in consistent profitability and execution risks.
View details
A
Advait Energy Transitions Ltd
Advait Energy Transitions Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
H
Hi-Tech Pipes Ltd
Hi-Tech Pipes Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
M
Meghmani Organics Ltd
Meghmani Organics Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
W
Wonder Electricals Ltd
Wonder Electricals Ltd presents several risks that outweigh its potential rewards, making it a risky investment at this time.
View details
D
DISA India Ltd
DISA India Ltd shows potential with a decent score, but investors should be cautious of execution risks and market sentiment.
View details
T
Thejo Engineering Ltd
Thejo Engineering Ltd shows potential but faces several challenges that could hinder growth and profitability. Caution is advised for investors.
View details
S
SPML Infra Ltd
SPML Infra Ltd shows potential in a growing sector but faces significant risks in profitability and execution, making it a risky investment.
View details
U
Ugro Capital Ltd
Ugro Capital Ltd shows potential but faces challenges in growth consistency and profitability metrics.
View details
I
Indian Hume Pipe Company Ltd
The Indian Hume Pipe Company Ltd shows potential in a growing sector, but faces challenges in growth consistency and market sentiment.
View details
D
Deccan Gold Mines Ltd
Deccan Gold Mines Ltd shows potential but is hindered by financial inconsistencies and market risks.
View details
E
Exicom Tele-Systems Ltd
Exicom Tele-Systems Ltd faces significant challenges in profitability and growth consistency, making it a risky investment at this time.
View details
C
Colab Platforms Ltd
Colab Platforms Ltd shows promise in a growing sector, but faces challenges in profitability and execution risks.
View details
Business Overview
Windlas Biotech Ltd is a leading Indian pharmaceutical company specializing in contract manufacturing and development of high-quality generic medicines. With a strong focus on innovation and quality, it caters to both domestic and international markets, ensuring accessibility to essential healthcare solutions. The company is committed to enhancing patient outcomes through its diverse portfolio of products, including formulations across various therapeutic segments. Windlas Biotech stands out for its state-of-the-art facilities and adherence to global regulatory standards, making it a trusted partner in the healthcare industry.
- Leading player in the Indian pharmaceutical sector
- Focus on high-quality generic medicines
- Strong commitment to innovation and quality
- Diverse product portfolio across therapeutic segments
- State-of-the-art manufacturing facilities
- Adherence to global regulatory standards
Investment Thesis
Windlas Biotech Ltd presents a compelling investment opportunity due to its credible promoter group, significant growth potential in digital services, and attractive valuation compared to peers. These factors position the company for sustained growth and profitability in the evolving biotech landscape.
- Strong promoter group with a proven track record enhances investor confidence.
- Digital services segment shows robust growth potential, tapping into modern healthcare trends.
- Valuation metrics indicate Windlas is undervalued compared to industry peers, presenting a buying opportunity.
- Established market presence and diverse product portfolio mitigate risks.
- Positive industry outlook supports long-term growth prospects.
Opportunity vs Risk
Opportunities
- Growing demand for biotech products
- Expansion into international markets
- Strong R&D pipeline
- Strategic partnerships with healthcare firms
- Government support for biotech sector
Risks ⚠️
- Regulatory hurdles in drug approvals
- Intense competition in biotech
- Dependency on a few key products
- Market volatility affecting stock price
- R&D failures leading to financial loss
Peer Perspective
Windlas Biotech Ltd trades at a discount compared to peers like Biocon and Dr. Reddy's, primarily due to margin pressures. A sustained improvement in profitability and growth could trigger a rerating in its valuation.
Future Outlook
Windlas Biotech Ltd is well-positioned for growth, driven by its innovative product pipeline and expanding market presence. Successful execution and stringent cost control will be crucial in maximizing shareholder value moving forward.
AI FAQs for Retail Users
- Q: What does Windlas Biotech Ltd do?A: Windlas Biotech Ltd is involved in manufacturing and marketing pharmaceutical products, including generic medicines.
- Q: Is Windlas Biotech Ltd a good investment?A: Investing decisions should consider your financial goals and risk tolerance; research the company thoroughly.
- Q: What are the risks of investing in Windlas Biotech Ltd?A: Risks include market volatility, regulatory changes, and competition in the pharmaceutical sector.
- Q: How can I buy shares of Windlas Biotech Ltd?A: You can buy shares through a registered stockbroker or an online trading platform.
- Q: What is the financial health of Windlas Biotech Ltd?A: Review their financial statements and reports for insights into profitability and debt levels.
📊 Stock Investment Checklist (100 Points)
Windlas Biotech Ltd • Updated: 2025-09-18 01:47:06
-
10BusinessHighThe biotech sector is growing, but Windlas faces competition and regulatory challenges.
-
10GrowthHighRevenue growth has been consistent, but profit margins are under pressure.
-
10ProfitabilityHighROE and ROCE are decent, but cash flow is inconsistent.
-
8ValuationHighValuation metrics are higher than peers, indicating potential overvaluation.
-
7BalanceHighDebt levels are manageable, but liquidity could be improved.
-
6GovernanceGoodPromoter holding is strong, but there are concerns about disclosures.
-
5DriversGoodGrowth drivers exist, but execution risks are significant.
-
5TechnicalsGoodMarket sentiment is mixed, with low liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
Windlas Biotech Ltd shows potential in a growing sector, but faces challenges in profitability and valuation. Caution is advised.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 70/100
- Growth Potential: 75/100
- Profitability: 65/100
- Governance: 60/100
- Market Confidence: 68/100